These frequent variants, unique to cancer and high-risk patients, which should be noted as potential PVs, included TP53 c.799C>T, APC c.3183_3187delACAAA, ATM c.1516G>T, BRCA2 c.3170_3174del, c.122C>T, c.5909C>T and c.5557dup, CDKN2A c.238C>T, MSH2 c.1964del, MSH6 c.733A>T deletion of the whole of exon 16 of MLH1, MUTYH c.544C>T and c.734G>A, and PALB2 c.1102A>T. This evidence concerns the gene MUTYH and cancer.